Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 6:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–640 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: ipilimumab Clear all
Terminated Phase 2 Interventional Results available

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

NCT02203604
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
aldesleukin, ipilimumab, laboratory biomarker analysis
Biological · Other
Lead sponsor
CINJRegulatory
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
6
States / cities
Maywood, Illinois • Boston, Massachusetts • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional

Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

NCT00261365
View directory record Official record
Conditions
Unresectable Stage III or IV Malignant Melanoma
Interventions
Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
Palm Springs, California • Santa Monica, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional

Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

NCT00871481
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
ipilimumab, cyclophosphamide, biopsy, aldesleukin, immunohistochemistry staining method, polymerase chain reaction, immunoenzyme technique, therapeutic cytotoxic T lymphocytes
Biological · Drug · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Oct 28, 2026, 6:41 PM EDT
Withdrawn Phase 2 Interventional

Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors

NCT05284214
View directory record Official record
Conditions
Solid Tumor, Solid Tumor, Adult
Interventions
Sargramostim, Ipilimumab-containing therapy
Biological
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

NCT02970981
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Oct 28, 2026, 6:41 PM EDT
Suspended Not applicable Interventional

The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)

NCT04866810
View directory record Official record
Conditions
Melanoma
Interventions
Intervention Arm, Control
Behavioral
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Loma Linda, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Phase 1Phase 2 Interventional

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00058279
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
aldesleukin, ipilimumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 28, 2026, 6:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers

NCT04416568
View directory record Official record
Conditions
Malignant Rhabdoid Tumor, Rhabdoid Tumor of the Kidney, Epithelioid Sarcoma, Chordoma (Poorly Differentiated or De-differentiated), Atypical Teratoid/Rhabdoid Tumor, Other INI1 Negative Tumors (With PI Approval), Other SMARCA4-deficient Malignant Tumors (With PI Approval)
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
6 Months to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

NCT02996110
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Ipilimumab, Relatlimab, BMS-986205, BMS-813160
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
New Haven, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Oct 28, 2026, 6:41 PM EDT
Recruiting Phase 2 Interventional

Cryoablation+Ipilimumab+Nivolumab in Melanoma

NCT05779423
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Ipilimumab, Nivolumab, Cryoablation
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Terminated Phase 2 Interventional Results available

An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer

NCT02750514
View directory record Official record
Conditions
Advanced Cancer
Interventions
Nivolumab, Dasatinib, Relatlimab, Ipilimumab, BMS-986205
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
35
States / cities
Duarte, California • Los Angeles, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Oct 28, 2026, 6:41 PM EDT
Terminated Phase 1 Interventional Results available

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

NCT01810016
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma
Interventions
Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide, NY-ESO-1 OLP4 Vaccine with Poly-ICLC
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
New York, New York • Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma

NCT03068455
View directory record Official record
Conditions
Melanoma
Interventions
nivolumab, ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Enrollment
1,844 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
33
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 28, 2026, 6:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

NCT01134614
View directory record Official record
Conditions
Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions
Ipilimumab, Sargramostim
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2027
U.S. locations
257
States / cities
Birmingham, Alabama • Palo Alto, California • Rancho Mirage, California + 197 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 6:41 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

NCT03445533
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Tilsotolimod with Ipilimumab
Drug
Lead sponsor
Idera Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 28, 2026, 6:41 PM EDT
Completed Phase 2 Interventional

Study of MDX-010 in Stage IV Breast Cancer

NCT00083278
View directory record Official record
Conditions
Breast Cancer, Adenocarcinoma
Interventions
MDX-010
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
14
States / cities
San Diego, California • Indianapolis, Indiana • Jeffersonville, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Oct 28, 2026, 6:41 PM EDT